Table 1.
Data analysis of included studies
| Study | N | Male | Female | Age (average) | Resource of tumor | Volume of MPE(N) | Quality of Life (KPS) | End point | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NSCLC | SCLC | Gastrointestinal tumor | Breast cancer | Lymphoma | Others | ||||||||
| Changjie H 2001 [15] | 60 | 44 | 16 | 30–76 | 27 | 4 | 11 | 10 | 8 | Moderate-large | > 60 | ORR, DCR, AEs | |
| Xiuzhi Y 2001 [16] | 60 | 24 | 36 | 40–75 | 56 | 0 | 0 | 0 | 4 | – | – | ORR, DCR, AEs | |
| Zhuo S 2004 [17] | 62 | – | – | – | 55 | 0 | 0 | 0 | 7 | – | > 50 | ORR, DCR, QOL, AEs | |
| Junyan W 2005 [18] | 82 | 57 | 25 | 33–78 | 68 | 0 | 10 | 0 | 4 | – | > 50 | ORR, DCR, AEs | |
| Haiying X 2009 [19] | 63 | 35 | 28 | 35–71 | 63 | 0 | 0 | 0 | 0 | – | > 60 | ORR, DCR, AEs | |
| Xiaoxia H 2009 [20] | 72 | – | – | – | 65 | 0 | 0 | 0 | 7 | Small (8) Moderate (39) Large (25) |
> 60 | ORR, DCR, QOL, AEs | |
| Lizheng C 2009 [21] | 86 | 62 | 24 | 25–75 | 23 | 0 | 27 | 17 | 8 | 11 | Large(29) Moderate(57) |
> 60 | ORR, DCR, AEs |
| Jinguang C 2009 [22] | 62 | 28 | 34 | 41–77 | 52 | 10 | 0 | 0 | 0 | 0 | – | > 60 | ORR, DCR, AEs |
| Junfeng W 2010 [23] | 82 | 48 | 34 | 30–80 | 54 | 0 | 15 | 0 | 13 | Large(56) Moderate(26) |
> 60 | ORR, DCR, AEs | |
| Jingping Z 2010 [24] | 124 | 80 | 44 | 47–73 | 124 | 0 | 0 | 0 | 0 | Large(84) Moderate(40) |
> 60 | ORR, DCR, AEs | |
| Cheng X 2010 [25] | 62 | 28 | 34 | 19–81 | 40 | 0 | 9 | 13 | – | > 70 | ORR, DCR, AEs | ||
| Fang S 2011 [26] | 60 | 31 | 29 | 38–76 | 41 | 8 | 2 | 7 | 2 | 0 | Large(34) Moderate(17) |
> 40 | ORR, DCR, QOL, AEs |
| Xueling L 2011 [27] | 68 | 40 | 28 | 30–75 | 40 | 10 | 8 | 0 | 10 | – | > 60 | ORR, DCR, AEs | |
| Yan Q 2011 [28] | 76 | 45 | 31 | 46–77 | 76 | 0 | 0 | 0 | 0 | – | > 60 | ORR, DCR, AEs | |
| Li J 2013 [29] | 73 | 40 | 33 | 35–74 | 31 | 16 | 26 | 0 | 0 | Large(41) Moderate(32) |
> 60 | ORR, DCR, QOL, AEs | |
| Lijie H 2014 [30] | 60 | 38 | 22 | 39–78 | 60 | 0 | 0 | 0 | 0 | Large | > 50 | ORR, DCR, QOL, AEs | |
| Miao H 2016 [31] | 61 | 40 | 21 | 38–75 | 42 | 0 | 8 | 6 | 5 | Large | > 60 | ORR, DCR, AEs | |
| Baohua Y 2017 [32] | 66 | 35 | 31 | 42–76 | – | – | – | – | – | – | – | > 60 | RR, DCR |
N number of patients, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, MPE malignant pleural effusions, KPS karnofsky physical status score, ORR objective response rate, DCR, disease control rate, QOL quality of life, AEs adverse effects